{ event: "article_read", name: `Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice`, author: ``, tags: `Cardiovascular | Atherothrombosis`, publication_date: ``, interaction_type: "content" }
Ticagrelor vs Clopidogrel in ACS patients undergoing PCI in routine clinical practice
Main Takeaway
Risk for net adverse clinical events (NACE) was not significantly different between ticagrelor at 12 months compared with clopidogrel
Study population: 62,580 patients with acute coronary syndrome (ACS) who underwent percutaneous coronary intervention (PCI) in routine clinical practice
Ticagrelor was associated with higher risks for haemorrhagic events and dyspnoea vs clopidogrel
Why This Matters
Recent observational studies question whether ticagrelor vs clopidogrel is associated with better outcomes in routine clinical practice
Current guidelines: recommend ticagrelor with aspirin in preference to clopidogrel in patients with ACS
Study Design
Retrospective cohort study: 183,579 patients (age range, 30-89 years) with ACS who underwent PCI and received ticagrelor or clopidogrel
Patients were matched using propensity score:
Ticagrelor (n=31,290)
Clopidogrel (n=31,290)
Primary endpoint: NACE at 12 months
Ischaemic events [recurrent acute myocardial infarction, revascularisation or ischaemic stroke]
Haemorrhagic events [haemorrhagic stroke or gastrointestinal bleeding]
Secondary outcomes: NACE or mortality, all-cause mortality, composite ischaemic events, composite haemorrhagic events, individual components of the primary outcome, dyspnoea at 12 months
Key Results
95.5% of matched patients used aspirin with ticagrelor or clopidogrel among the 31,290 propensity-matched pairs
The risk for NACE was not significantly different between ticagrelor and clopidogrel groups (HR, 1.05; 95% CI, 1.00-1.10; P=0.06)
No significant difference was found between the 2 groups for:
NACE or mortality (HR, 1.03; 95% CI, 0.98-1.08; P=0.21)
The study did not include information on aspirin dosage, angiographic findings, or PCI procedure
The burden of overall bleeding events could have been underestimated or overestimated
Neither the proportion of patients who switched antiplatelet drugs nor its effects were quantified
The effect of pre-treatment with an antiplatelet agent was not assessed
The mortality rate might have been underestimated
Patients who used prasugrel for dual antiplatelet therapy were not included
You SC et al. Association of Ticagrelor vs Clopidogrel With Net Adverse Clinical Events in Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. JAMA. 2020;324(16):1640-1650. doi:10.1001/jama.2020.16167.
By clicking on this link, you will be leaving Campus Sanofi website and going to another, entirely independent website. Please note: Sanofi provides these links as a service to its website visitors and users; however, Sanofi takes no responsibility for the information on any website but their own.
